Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. In summary, 2023 could be a very exciting year for life sciences. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023. .

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

MAY 5, 2023

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. In contrast to DNA-based reprogramming and gene editing, the mRNA-based approach does not expose cells to expensive and potentially harmful viruses or DNA vectors.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

XTalks

MAY 12, 2021

Read the full articles here: Epigenetic Editing with CRISPR Might Be Easier Than We Thought. New Study Looks at Effects of ADHD Drugs in Preschoolers. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Gene Expression Gene DNA 52

pharmaphorum

DECEMBER 14, 2022

Healthcare commercial services agency Eversana announced that Sy Pretorius (as pictured), a 25-year life sciences veteran, will join the company as chief operating officer and president of outsourced solutions. November saw the launch of a new private equity team in life sciences at J.P. Eversana taps new COO.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

NOVEMBER 1, 2023

DDW’s Diana Spencer meets Dr Stephen Jones, Research Professor and Group Leader at the EMBL Partnership Institute for Genome Editing Technologies at Vilnius University’s Life Sciences Center. DS: What drug discovery breakthrough has been most impactful to your research? SJ: CRISPR is the obvious one.

Gene Editing 59

Gene Editing Research Gene Genome 59

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The 2024 Drugs to Watch, are: 1.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

BioTech 365

OCTOBER 22, 2020

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & an immuno-centric discovery life science company with a … Continue reading →

Gene Editing 52

Gene Editing Immune Response Life Science Engineer 52

Drug Discovery World

NOVEMBER 27, 2023

By Anis H Khimani , PhD, Senior Strategy Leader, Life Sciences strategy group, Revvity, Inc. Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Stable clonal cell banks are used for GMP production of the final drug product.

Production 59

Production Engineer Gene Editing Gene 59

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

pharmaphorum

OCTOBER 7, 2020

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9. In 2011, Emmanuelle Charpentier and Jennifer Doudna had no idea that their first meeting, in a café in Puerto Rico, would be life-changing.

Gene Editing 105

Gene Editing Bacteria DNA Gene 105

XTalks

JANUARY 26, 2024

Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. Overcoming drug resistance: A major challenge in cancer treatment is the development of resistance to chemotherapy drugs.

Research 118

Research Gene Editing Gene Genetics 118

XTalks

MARCH 28, 2024

Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council – Xtalks Life Science Podcast Ep. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

pharmaphorum

NOVEMBER 23, 2021

It is also close to Cambridge University, seen as one of the world’s leading life sciences research centres, as well as the city’s Addenbrookes Hospital, an important centre for clinical trials in the National Health Service.

Gene Editing 105

Gene Editing Life Science Pharma Companies Clinical Trials 105

Drug Discovery World

SEPTEMBER 6, 2022

As we look to the future, many advanced therapy players are sticking to traditional cell and gene technologies like autologous cell therapies and gene therapy using adeno-associated viral vectors, but some are branching out to other models like allogeneic cell therapies, non-viral delivery methods and gene-editing technologies.

Gene Therapy 52

Gene Therapy Gene Gene Editing Manufacturing 52

XTalks

NOVEMBER 3, 2023

After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based gene therapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw. CRISPR works as genetic scissors to edit parts of the genome.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

XTalks

NOVEMBER 30, 2023

In 2022, the US Food and Drug Administration (FDA) granted approval to the medication Sunlenca (lenacapavir) for adults living with multi-drug resistant HIV-1 infection. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

NOVEMBER 24, 2023

While some breakthroughs may not have immediate commercial applications, the intellectual freedom that academia fosters is often the initial driver of innovation and improvement, which life sciences R&D can take that one step further. This includes areas such as stem cell therapy, tissue engineering, and gene editing.

Research 59

Research Life Science Gene Editing Vaccination 59

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

The Pharma Data

JANUARY 12, 2021

In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Photo courtesy of Bayer. The platform is already bearing fruit.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

pharmaphorum

JULY 1, 2021

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe. The next decade is where it really starts to get interesting, as we see more and more ‘synbio’-enabled drugs enter clinical trials.

Gene Editing 88

Gene Editing Engineer Development Gene 88

Drug Discovery World

MAY 23, 2023

Beyond 2023, I think we’ll continue to see more innovations driven by improvements in gene editing and biological understanding.” Upskilling Currently, skill sets are one of the general challenges in the life sciences. Another opportunity White sees is shortened processes with autologous therapies.

Gene Therapy 52

Gene Therapy Gene Gene Editing Production 52

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

SEPTEMBER 6, 2022

The cell and gene therapy industry has experienced exponential growth in the last three years and as funding for the field continues to break records there are no signs of a slowdown. With 2,261 ongoing clinical trials in regenerative medicine, the FDA expects to approve 1 between 10 and 20 new cell and gene therapies a year by 2025.

Gene Therapy 52

Gene Therapy Gene Manufacturing Clinical Trials 52

XTalks

DECEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. Both gene therapies are approved for individuals 12 years of age and older with sickle cell disease. Both therapies will be available in early 2024. million after discounts.

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

JULY 14, 2022

A significant disruption to these networks can alter the expression of immune genes and result in disease. Mapping networks helps us understand the impact of a disruption and its effect throughout the network, or how a drug can impact numerous proteins at once.

Gene 98

Gene Regulation Protein Gene Editing 98

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. in Life Sciences and Chemistry from the Weizmann Institute of Science. NEW YORK , Dec. 29, 2020 /PRNewswire/ — Scopus BioPharma Inc. from the Harvard T.H.

Gene Therapy 52

Gene Therapy Life Science Gene Gene Editing 52

XTalks

FEBRUARY 27, 2024

There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

Drug Discovery World

APRIL 3, 2023

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. Equally, the controlled chemistry of Optimer offers the ability for precise aptamer-drug ratios, with conjugation at specific sites on the molecule to simplify therapeutic manufacture.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

JANUARY 26, 2023

Even when those assets are excluded, the average ROI for 2021 was still double the 2022 projections.   “Aside from Covid-19, the fall in projected ROI has been driven by a combination of factors, ranging from high-value drugs securing approvals and entering commercialisation, to an increase in cycle times for drugs still in development.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Pharmaceutical Technology

FEBRUARY 13, 2023

Although recently approved drugs can treat seizures more safely, they do not treat the comorbidities that patients experience. Several biotech companies and researchers are now exploring medical devices and gene therapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome.

Research 264

Research Gene Gene Therapy Genome 264

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JANUARY 4, 2024

The adeno-associated viral (AAV) vector-based gene therapy received approval in Canada for the treatment of adults aged 18 years or older with moderately-severe to severe hemophilia B who are negative for neutralizing antibodies to variant AAV serotype Rh74, Pfizer Canada revealed in its announcement of the approval.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

Drug Discovery World

OCTOBER 7, 2022

Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science.

HR 52

HR Research Drugs Development 52